Release date: 12 May 2009
Promoter – Financial Intermediary
A family-owned, mid-sized pharmaceutical company.Location
Description
The project concerns the investment in research and development of new pharmaceutical compounds in the area of CNS (Central Nervous System), Respiratory Diseases and Metabolic Diseases (in particular diabetes).
Objectives
New pharmaceutical products in the area of CNS, Metabolism and Respiratory.
Sector(s)
Proposed EIB finance (Approximate amount)
EUR 400 million.
Environmental aspects
R&D activities included in the project will not materially change current R&D practice and will be carried out within existing facilities, making use of existing laboratories, pilot plants, clinical centres, etc. An EIA therefore is not required by EU Directive 97/11. Compliance of R&D activities with relevant EU legislation in particular in regards to animal testing will also be verified during appraisal.
Procurement
The promoter is a private company not operating in the Utilities sector, and is thus not covered by EU Directives on procurement. Procedures followed will be verified during appraisal.
Status
Signed - 28/10/2009
Disclaimer
Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).